🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Great session with our international #SCAD group on #Sinergy2024 ▶️Women in Cardiology- Specifities of acute coronary syndrome in women Aleksandra Djokovic

Resistance Exercise Training in Individuals With and Without Cardiovascular Disease: 2023 Update: A Scientific Statement From the American Heart Association: Circulation 🥸 On lifting weights = resistance exercise training in people with and without CVD 😱 Great!!! 👇👇👇

State-of-the-art Review of #gene therapy for cardiac diseases Discover the latest advancements in #cardiac gene therapy including methods, challenges, future directions, & more bit.ly/3XYrWaq CVR Tomasz Guzik Mike Drozd Glen Pyle | #WomensHeartHealth ❤️‍🩹🖇️ Sarah Brown #CardiovascularResearch

CVPrevInterv Dr Shrilla Banerjee MD FRCP 💙 MI in the young..not one entity & includes premature ASCVD Interesting to see the The Lancet commission recommendations for premature IHD including gene silencing & injectables to address factors like obesity Rasha Al-Lamee A/Prof Sarah Zaman Davide Capodanno

Are all stents the same for high bleeding risk (HBR) patients? BioFreedom, Resolute Onyx, Synergy, and Xience are approved for HBR patients by both the European Commission and FDA. While Orsiro Mission has strong evidence for HBR use, it lacks specific HBR regulatory approval.

The first EuroIntervention issue of 2025 features a clinical consensus statement from the EAPCI, in collaboration with the European Society of Cardiology Working Group on Cardiovascular Surgery, outlining procedural and technical requirements to enhance the efficacy and safety of PCI in high-risk

The most fantastic knowledge quiz at CardioS 2025. Many thanks to our fabulous organizers Aleksandra Djokovic Aleksandra Djokovic and MarinaOstojic and congrats to the happy winners 💪🍀👍😊

First day at #ACC25, here are the results of 10 trials presented today. I counted 3 NEJM, 1 Lancet, and 1 JAMA. WARRIOR: Intensive medical therapy did not reduce major CV events at five years in women with suspected INOCA. STRIDE: Semaglutide improved walking distance, symptoms,

🔴 ASE Recommendations for Evaluation of Prosthetic Valves with Echo & Doppler Ultrasound 🔹Normal Flow Patterns & Essential Parameters in the Evaluation Prosthetic Aortic Valves Prosthetic Mitral Valves Prosthetic Tricuspid Valves Prosthetic Pulmonic Valves

Clinical management and therapeutic optimization of patients with heart failure with reduced ejection fraction and low blood pressure. A clinical consensus statement of the Heart Failure Association (HFA) of the ESC onlinelibrary.wiley.com/doi/epdf/10.10…

Inflammation fuels 🫀 disease—but what if we could stop it at the source? This #JACCAsia review explores how blocking CGAS-STING1 immune pathway could prevent cardiac dysfunction & improve survival. Game-changer for CV therapy? 🔍 jacc.org/doi/10.1016/j.… #cvPrev #CVD AJ Marian

Age-specific troponin thresholds: considerations for the fifth universal definition of myocardial infarction in EHJ. doi.org/10.1093/eurhea… @ESCardio European Society of Cardiology Journals #age #5UDMI John William McEvoy

🫀 Top 10 Updates from #HeartFailure2025 Congress! Here’s what every cardiologist & healthcare provider needs to know about the latest in heart failure treatment and management: 👇🧵 [1/11]

In PROSPECT II, elevated TC, LDL-C, & non-HDL-C were strongly associated w/ pancoronary atherosclerosis & lipid deposition, whereas elevated Lp(a) was strongly associated w/ the presence of focal vulnerable plaques. Get more details: bit.ly/43lbEMP #JACC JACC Journals